Development of palliative care is less effective for patients with hematologic malignancies. Limited data is available for end of life care in this population, moreover with thrombocytopenic patients. Thrombopenia is a frequent complication, specific of bone marrow involvement in those diseases or its treatments. Yet, a few studies was interested in, whereas platelet transfusion is the only treatment indicated. As it represent a scarce, limited resource, the ethical principles are in conflict in this setting.

The purpose of this study was to describe retrospectively platelet transfusion in the six last few month of life of patients with hematologic malignancies at the CHU of Besançon (France) between 01/07/15 and 31/12/16.

Inclusion Criteria:

• patient with hematological malignancies
• transfused in platelet at least once in the last 6 months of life
• hospitalised or follow up at the CHU of Besancon at least once
• dead during the period of the study

Exclusion Criteria:

• patient with other oncologic malignancies
• not transfused in platelet in the last 6 months of life
• never hospitalised or follow up at the CHU of Besancon
• alive

patient with hematological malignancies,transfused in platelet at least once in the last 6 months of life, hospitalised or follow up at the CHU of Besancon at least once and dead during the period of the study

patient were dead during the period of recruitment. Characteristic of patient could be used for other purpose